Lancet Oncol: Ointoju single anti-DHAP combination therapy to treat sleeve cell lymphoma.

The treatment of suite cell lymphoma with AoIntoju monotherapy has shown good efficacy.
researchers recently examined the effects of four rounds of Ottoju monoanti-DHAP (dexamisone, high-dose agarosetide and cisplatin) on patients' micro-disease residues.
LyMa-101 for Phase II clinical trials in 28 hospitals in France.
newly diagnosed patients with set cell lymphoma eligible for an introphy stem cell transplant were involved in receiving 4 cycles of AoInto-DHAP combined therapy before the transplant (intravenous injection of 1000 mg/m 2 Oyento-Phosphorus monoantigen on day 1, 8 and 15 of cycle 1 and 2, 3, 4 cycles; Injection of 2g/m2 glycosine every 12 hours, continuous infusion of 24h, or Osali platinum 130 mg/m2, on the first day, followed by 3 years of Aointojutin monoantigen maintenance therapy (1000 mg/m2 every two months), followed by Ointtobearto monoantigen maintenance therapy based on micro-disease residues.
result of the study was a four-cycle combined treatment with negative residues of micro-diseases in the bone marrow.
if the residual negative rate of bone marrow micro-disease is 70% or higher, the combined DHAP of Ointojuzhu is considered effective.
86 patients participated in the study from November 29, 2016 to May 2, 2018.
81 patients completed induction therapy, 73 received induced stem cell transplants and 69 received maintenance therapy.
of the 73 patients, 55 (75%) remained negative for minor diseases in the bone marrow at the end of induction.
According to the programme definition, in 73 patients, 18 (25%) patients tested positive for micro-disease residues in bone marrow, of which 12 patients tested positive for bone marrow residues, 2 patients progressed during induction and 4 patients did not have residual assessment.
the most common level 3-4 treatment adverse reactions are anemia and neutral granulocyte reduction.
58 serious adverse events occurred during the induction phase and there were no treatment-related deaths.
study, the combination therapy of Ointoju monoanto-DHAP can effectively reduce the positive rate of bone marrow micro-disease in patients with heterocytic lymphoma who meet the transplant criteria.
.